Key facts, as of
As of October 13, 2026, Abbott Laboratories (ABT) trades at $101.82, down 23.2% over the past year. Its 52-week range runs from $81.97 to $133.34; the price is 23.6% below that high. It is 28.6% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +182.1%, against +312.9% for the S&P 500 (SPY). It sits 1.4% below its 200-day average of $103.23, the usual sign of a long-term downtrend. Its 30-day volatility is 20.9% annualized, which we rate medium risk. It has a trailing P/E of 33.6 and a dividend yield of 2.48%.
Cite: Portfolio Terminal, "Abbott Laboratories (ABT) stock analysis", 2026-10-13. https://portfolio-terminal.com/analyse/abt
Where it trades today
trading 39% of the way up its 52-week range
How the price has moved
How far it is from its record
Abbott Laboratories (ABT) is 28.6% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +182.1%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ABT trades at 33.6x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- ABT carries a beta of 0.58, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ABT is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ABT.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ABT come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ABT. Last refresh: Oct 13, 2026, 9:18 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Abbott Laboratories does
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective…
What analysts expect
ABT carries a strong buy consensus from 26 analysts, with an average price target of $120.72 versus $101.82 today (+18.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ABT generated $46.58B in trailing revenue (13.0% year over year), with a 11.6% net margin, and $7.21B of free cash flow, against $27.12B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $44.33B | $25.01B | $8.05B | $6.52B | $3.76 | $7.39B |
| 2024 | $41.95B | $23.24B | $6.83B | $13.40B | $7.74 | $6.35B |
| 2023 | $40.11B | $22.13B | $6.48B | $5.72B | $3.30 | $5.06B |
| 2022 | $43.65B | $24.51B | $8.36B | $6.93B | $3.99 | $7.80B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ABT is in 9 of the 30 ETFs we track. It weighs most in SCHD: 3.81% of the fund, holding #12 of 100.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ABT beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 4.0% below its 50-day average and 1.4% below its 200-day.
- The 50-day crossed above the 200-day on 2026-09-16 (a “golden cross”).
- RSI at 50 is neither stretched nor washed out.
- The nearest ceiling is $104.55 (+2.7%), the nearest floor $100.60 (-1.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is ABT a good investment in 2026?
Abbott Laboratories trades at a P/E ratio of 33.6, with medium volatility (20.9% annualized). The stock is in a consolidation phase.
What is the risk level of ABT?
Based on 30-day volatility of 20.9%, ABT has MEDIUM risk. Beta of 0.58 indicates lower sensitivity to market movements than average.
Does ABT pay dividends?
Yes, Abbott Laboratories has a dividend yield of 2.48%.
How far is ABT from its all-time high?
Abbott Laboratories is 28.6% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +182.1%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold ABT?
9 of the 30 popular ETFs we track hold Abbott Laboratories. The largest weights: SCHD (3.81%), XLV (2.83%), VIG (0.82%), VYM (0.77%) and VTV (0.70%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is ABT?
0.29%, as of August 31, 2026: ABT is holding #58 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.90 in Abbott Laboratories.
What is the analyst price target for ABT?
The average analyst price target for Abbott Laboratories (ABT) is $120.72 based on 26 analyst estimates, about 18.6% above the current price of $101.82. The published range runs from $103.00 to $135.00.
How much revenue does ABT generate?
Abbott Laboratories reported $46.58B in trailing twelve-month revenue. Revenue growth is running at 13.0% year over year. Net margin sits at 11.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ABT with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.